Pyridoxal phosphate prevents progression of diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2165-2174

  Nakamura, Sakurako ^a   Li, Hongyan ^a,b   Adijiang, Ayinuer ^a   Pischetsrieder, Monika ^c   Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Advanced glycation end products (AGEs); Diabetic nephropathy; Pyridoxal 5 phosphate (PLP); Receptor for advanced glycation end products (RAGE); Transforming growth factor 1 (TGF 1)

Indexed keywords

3 DEOXYGLUCOSONE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 1; DEOXYGUANOSINE DERIVATIVE; FIBRONECTIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAMINE; PYRIDOXINE; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG STRUCTURE; FEMALE; FIBROSING ALVEOLITIS; IMMUNOHISTOCHEMISTRY; KIDNEY HYPERTROPHY; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; DIABETIC NEPHROPATHIES; FEMALE; FIBRONECTINS; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; PYRIDOXAL PHOSPHATE; PYRIDOXAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN B 6;

EID: 34547843594     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm166     Document Type: Article

References (40)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
2. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complication in individual with long standing IDDM. Diabetes 1992; 41: 1286-1292
3. Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187-194
4. Nokura K, Koga H, Yamamoto H et al. Dialysis-related spinal canal stenosis: A clinicopathological study on amyloid deposition and its AGE modification. J Neurol Sci 2000; 178: 114-123
5. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 1992; 267: 931-939
6. Niwa T, Katsuzaki T, Miyazaki S et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-1280
7. Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, Horiuchi S. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: A new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 2003; 10: 1-6
8. Soulis-Liparota T, Cooper ME, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in the streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
9. Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-899
10. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 31-40
11. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). J Biol Chem 1997; 272: 5430-5437
12. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220: 113-119
13. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950
14. Stitt A, Gardiner TA, Alderson NL et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832
15. Sakurai T, Asakura T, Mizuno A, Matsuda M. Absorption and metabolism of pyridoxamine in mice. 2. Transformation of pyridoxamine to pyridoxal in intestinal tissues. J Nutr Sci Vitaminol 1992; 38: 227-233
16. Merrill AH,Jr, Henderson JM. Vitamin B6 metabolism by human liver. Ann NY Acad Sci 1990; 585: 110-117
17. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol 2005; 16: 144-150
18. Niwa T. 3-Deoxyglucosone: Metabolism, analysis, biological activity and clinical implication. J Chromatogr 1999; 731: 23-36
19. Miki Hayashi C, Nagai R, Miyazaki K et al. Conversion of Amadori products of the Maillard reaction to N-epsilon-(carboxymethyl) lysine by short-term heating: Possible detection of artifacts by immunohistochemistry. Lab Invest 2002; 82: 795-807
20. 2-carboxyethyl-2′-deoxyguanosine. Chem Res Toxicol 2004; 17: 1385-1390
21. Rogers KS, Higgins ES, Kline ES. Experimental diabetes causes mitochondrial loss and cytoplasmic enrichment of pyridoxal-phosphate and aspartate-aminotransferase activity. Biochem Med Metab Biol 1986; 36: 91-97
22. Okada M, Shibuja M, Yamamoro E, Murakami Y. Effect of diabetes on vitamin B6 requirement in experimental animals. Diabetes Obes Metab 1999; 1: 221-225
23. Gruden G, Thomas S, Burt D et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction. Proc Natl Acad Sci USA 1997; 94: 12112-12116
24. Gruden G, Zonca S, Hayward A et al. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000; 49: 655-661
25. Lassila M, Seah KK, Allen TJ et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: Role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-2138
26. Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-1823
27. Bucala R, Model P, Cerami A. Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 1984; 81: 105-109
28. 2-[1-(1-carboxy)ethyl] guanosine, an advanced glycation end product formed by the reaction of DNA and reducing sugars or L-ascorbic acid in vitro. Biochim Biophys Acta 1998; 1425: 478-484.
29. Seidel W, Pischetsrieder M. Reaction of guanosine with glucose under oxidative conditions. Bioorg Med Chem Lett 1998; 8: 2017-2022
30. 2-(1-Carboxyethyl)deoxyguanosine, a nonenzymatic glycation adduct of DNA, induces single-strand breaks and increases mutation frequencies. Biochem Biophys Res Commun 1999; 264: 544-549
31. Li H, Nakamura S, Miyazaki S et al. N(2)-carboxyethyl-2′-deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patient. Kidney Int 2006; 69: 388-392
32. Bucala R, Lee AT, Rourke L, Cerami A. Transposition of an Alu-containing element induced by DNA-advanced glycosylation endproducts. Proc Natl Acad Sci USA 1993; 90: 2666-2670
33. Bucala R, Model P, Russel M, Cerami A. Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. Proc Natl Acad Sci USA 1985; 82: 8439-8442
34. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes. Metab Res Rev 2001; 17: 436-443.
35. ε-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749
36. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and their receptors co-localize in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-628
37. Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 2003; 52: 1502-1510
38. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666
39. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137
40. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 2000; 275: 21177-21184